Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 PatientsCOVID-19 환자의 염증을 조절하는 말초 혈액 단핵 세포에서 변경된 유전자 발현 및 히스톤 메틸화의 특성화Article Published on 2022-04-152022-09-11 Journal: Journal of immunology (Baltimore, Md. : 1950) [Category] 유전자 메커니즘, [키워드] alteration Altered Analysis approved arginase Bone marrow cause caused characterization chromosome correlated COVID-19 COVID-19 disease COVID-19 patients COVID-19 treatment Cytokines death Dexamethasone dysregulated Epigenetic expression expression pattern expression patterns expressions gene expression profile Gene expression profiles Genes healthy control healthy controls histone histone methylation hospitalized COVID-19 patient hospitalized COVID-19 patients IL-1 IL-17 IL-1B IL-6 indicated Inflammation information inhibitor investigated kinase kinases long noncoding RNA majority mechanisms member Methylation miRNA pandemic of COVID-19 pathway Pathway analysis Pathways PBMC PBMCs peripheral Potential biomarker potential biomarkers proinflammatory cytokines protein S provide receptor Regulating Regulation significantly target targets TEC TGF-β therapeutic target therapeutic targets treat Treatment upregulated variations von Willebrand factor was increased [DOI] 10.4049/jimmunol.2101099 PMC 바로가기 [Article Type] Article
The effectiveness of dexamethasone as a combination therapy for COVID-19Review Published on 2022-04-132023-07-11 Journal: Acta pharmaceutica (Zagreb, Croatia) [Category] COVID19(2023년), [키워드] acute respiratory distress syndrome combination therapy Coronavirus disease 2019 Dexamethasone glucocorticosteroids immunosuppressive. SARS-CoV-2 [DOI] 10.2478/acph-2022-0030 [Article Type] Review
Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking studyArticle Published on 2022-04-072022-11-15 Journal: F1000Research [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] antiviral drug Antiviral effect arising B.1.1.7 B.1.351 B.1.351 variant B.1.617.2 Baricitinib binding binding affinity change conducted COVID-19 determine Dexamethasone drug Drug repurposing experiments Favipiravir Genetic variant investigated mitigate molecular docking molecular dynamics Mutation outbreak Previous studies public health Receptor binding domain Remdesivir residue SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant several variant Surface glycoprotein the SARS-CoV-2 virus Transmission treat virulence VOCs Wuhan, China [DOI] 10.12688/f1000research.109586.1 PMC 바로가기
Airway administration of bisphosphate and dexamethasone inhibits SARS-CoV-2 variant infection by targeting alveolar macrophages바이포스페이트와 덱사메타손의 기도 투여는 폐포 대식세포를 표적으로 하여 SARS-CoV-2 변이체 감염을 억제합니다Article Published on 2022-04-062022-09-11 Journal: Signal Transduction and Targeted Therapy [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] administration alveolar macrophage Dexamethasone Infection inhibit SARS-CoV-2 variant [DOI] 10.1038/s41392-022-00977-1 PMC 바로가기 [Article Type] Article
High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical TrialRandomized Controlled Trial Published on 2022-04-012022-10-04 Journal: Journal of Intensive Care Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome adjusted all-cause mortality analyzed ARDS ARMS caused clinical clinical trial coronavirus COVID-19 cumulative determine Dexamethasone dose enrolled Enrollment FIVE glycemic control group High-dose ICUs increase increase in infection rate intensive care unit intravenously low-dose mechanical ventilation median no difference Open-label outcome Patient patients with ARDS Primary outcome randomization Randomized Randomized controlled trial required respiratory secondary outcome significant difference significantly syndrome the mean Treatment Trial ventilator ventilator-free day VFD Viral pneumonia was increased weakness [DOI] 10.1177/08850666211066799 PMC 바로가기 [Article Type] Randomized Controlled Trial
Pharmacological treatment of COVID-19: an opinion paperCOVID-19의 약리학적 치료: 의견서Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] adalimumab Anakinra approach AZD7442 Azithromycin Banlanivimab Baricitinib BRII-196 BRII-198 canakinumab Casirivimab Certolizumab Ciganilmab Colchicine college Committee convalescent convalescent plasma COVID-19 Critical Dexamethasone drug drugs effective Efficacy English Etanercept etesevimab Evusheld Favipiravir fluvoxamine Golimumab help Hydroxychloroquine Imdevinab immune response Immunotherapy indication infliximab itolizumab Ivermectin Lemilumab Lopinavir Lopinavir/ritonavir Medicines metformin molnupiravir offer Pandemia pandemic Paxlovid PF-07321332 physician precocity prevented Ravulizumab Remdesivir Ritonavir ruxolitinib sarilumab SARS-CoV-2 Scientific Committee Sotrovimab Spanish the vaccine therapeutic Tixagevimab Tocilizumab Tofacitinib Treatment Vaccine virus Vitamin Vitamin D [DOI] 10.37201/req/158.2021 PMC 바로가기 [Article Type] Review
Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical TrialRandomized Controlled Trial Published on 2022-04-012022-10-04 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 임상, [키워드] adverse event Affair age all-cause mortality analyzed androgen antiandrogen Antibiotics Asthma baseline cardiovascular disease Care Cell chronic obstructive chronic respiratory clinical Clinical improvement Clinical outcome common Comorbidity convalescent plasma COVID-19 COVID-19 severity Department determine Dexamethasone diabete disease severity disorder double-blind Effect Efficacy end point End points enrolled Hemodialysis hospital Hospitalization Hospitalized hypertension IMPROVE Inpatient interim analysis intravenous fluids Invasive mechanical ventilation mechanical ventilation median men Mortality no difference no significant difference outcome Patient patients patients randomized Peritoneal dialysis Placebo placebo group placebo-controlled primary end point protease randomization Randomized randomized clinical trial reduce expression Remdesivir requiring supplemental oxygen saline placebo SARS-CoV-2 entry secondary Serious Adverse Event severity of COVID-19 Standard standard care stratified subcutaneous dose supplemental oxygen suppression temperature the placebo group therapy TMPRSS2 Trial usual care vasopressor support veteran with COVID-19 [DOI] 10.1001/jamanetworkopen.2022.7852 PMC 바로가기 [Article Type] Randomized Controlled Trial
Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edemaMulticenter Study Published on 2022-04-012023-07-07 Journal: Acta Diabetologica [Category] COVID19(2023년), [키워드] aflibercept combination therapy Dexamethasone Diabetic macular edema. [DOI] 10.1007/s00592-021-01824-5 PMC 바로가기 [Article Type] Multicenter Study
Kidney Transplant Recipient with Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Secondary to COVID-19 Pneumonia: A Case ReportResearch article Published on 2022-04-012022-10-05 Journal: Transplantation proceedings [Category] 진단, 치료제, [키워드] addition administration anorexia Antidiuretic antiviral therapy association Case report cause COVID-19 develop Dexamethasone diagnosed exclusion fatigue hormone hyponatremia Immunocompromised intravenous kidney transplant malaise management medications Modification nonspecific normalized Patient patients patients with COVID-19 Pneumonia Prophylaxis recipient report Result secondary bacterial infection secondary to secretion serum sodium Symptom syndrome Transplant treated ventilatory support Viral pneumonia [DOI] 10.1016/j.transproceed.2022.04.001 [Article Type] Research article
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic diseaseResearch article Published on 2022-04-012022-10-05 Journal: Medicina clínica [Category] 바이오마커, [키워드] Admission Anticoagulants approach ARDSsevere acute respiratory distress syndrome Biomarkers C-reactive protein CBCcomplete blood count chronic disease Chronic diseases complete blood count control group Coronavirus disease 2019 Corticosteroid COVID-19 COVID-19 patient COVID-19coronavirus disease 2019 CRP CRP level CRPC-reactive protein Dexamethasone diagnostic effective Effectiveness groups hematological hematological parameter identify Impact lab material mortality rate neutrophil count novel coronavirus disease Patient patients treated protocol protocols Result SARS-CoV-2severe acute respiratory syndrome coronavirus 2 severe acute respiratory distress syndrome severe acute respiratory syndrome coronavirus 2 severity significantly standard treatment statistically significant therapeutic Tocilizumab treated treating COVID-19 patient Treatment Treatment protocol was performed WBC [DOI] 10.1016/j.medcli.2022.02.013 [Article Type] Research article